Leukemia (includes ALL, AML, APL, CLL, CML, MDS, Myeloproliferative Disorders, Myelofibrosis)

Genetic Variations In A Fourth Gene Linked To Elevated Leukemia Risk In Hispanic Children

(St. Jude Children’s) Feb 14, 2019 - St. Jude Children’s Research Hospital scientists have completed one of the largest studies yet designed to advance understanding of why Hispanic children are more likely to develop leukemia and less likely to survive.

read press release

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response

(MarketWatch) Feb 14, 2019 - Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).

read article

WHO Warns of Fake Cancer Drug Made From Paracetamol

(The Guardian [UK]) Feb 12, 2019 - Pills that resemble Leukaemia drug Iclusig sold in Europe and Americas for £5,000 a pack.

read article

Scotland Says No To Yescarta, But Backs Kymriah

(Pharmaphorum.com [UK]) Feb 12, 2019 - Scotland’s cost-effectiveness watchdog has decided against making Gilead’s CAR-T therapy Yescarta routinely available to patients with two types of lymphoma, but gave a green light to Novartis’ rival Kymriah for a rare form of leukaemia.

read article

ImmunoGen Reports Recent Progress and 2018 Operating Results

(ImmunoGen) Feb 8, 2019 - Top-line data from phase 3 FORWARD I mirvetuximab soravtansine study on track for first half of 2019. Encouraging clinical data from novel IGN pipeline highlighted in two oral presentations at ASH 2018.

read corporate press release

Actinium Initiates Novel Phase 1/2 Combination Trial of Actimab-A and Venetoclax

(The Business Journals) Feb 5, 2019 - Combination trial at UCLA Medical Center supported by demonstrated synergy and mechanistic rationale of targeted radiation from Actimab-A with venetoclax in preclinical studies.

read article

CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update

(StreetInsider) Feb 1, 2019 - CTI BioPharma Corp. today announced that the Company will withdraw its European Marketing Authorization Application (MAA) for pacritinib as a treatment for myelofibrosis.

read article

New Study to Focus on Unique Needs of Acute Myeloid Leukemia Patients

(CSC) Jan 30, 2019 - The Cancer Support Community (CSC), a global nonprofit, is launching a unique research study focused on individuals diagnosed with Acute Myeloid Leukemia (AML), a cancer of the blood and bone marrow which accounts for approximately 19,520 new cases of cancer each year (American Cancer Society, 2018).

read press release

ASLAN Pharmaceuticals Announces Strategic Prioritisation Of Clinical Development Programs And Corporate Restructuring

(ASLAN) Jan 30, 2019 - ASLAN Pharmaceuticals, a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets, today announced a strategic corporate restructuring to focus its resources on its lead clinical programs: varlitinib in biliary tract cancer (BTC), ASLAN003 in acute myeloid leukaemia (AML) and ASLAN004 in atopic dermatitis. ASLAN will focus its resources on the late-stage development of varlitinib as a potential novel treatment for first- and second-line BTC. Enrolment in a global pivotal study of varlitinib in second-line BTC, the TreeTopp (TREatmEnT OPPortunity) study, was completed ahead of schedule in December 2018 and topline data is expected in the second half of 2019. ASLAN will be closing the ongoing single-arm second-line BTC study in China as it is now expected to read out after the TreeTopp study. If positive, data from the TreeTopp study will be used to submit a New Drug Application (NDA) in China, the US and other major geographies.

read corporate press release

Drug Compound Could Be Next-Generation Treatment For Aggressive Form Of Leukemia

(Purdue University) Jan 28, 2019 - Researchers have been struggling for years to find a treatment for patients who have a recurrence of acute myeloid leukemia (AML), an aggressive blood cancer that is one of the most lethal cancers.

read press release

FACIT and Triphase Accelerator Announce New Partnership with Celgene for First-in-Class WDR5 Leukemia Therapy

(Markets Insider) Jan 29, 2019 - Triphase Accelerator, together with its majority shareholder FACIT, today announced a new strategic collaboration with Celgene for a first-in-class preclinical therapeutic targeting the WDR5 protein for the treatment of blood cancers including leukemia.

read article

U.S. FDA Approves IMBRUVICA® (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia

(Janssen) Jan 28, 2019 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of IMBRUVICA® (ibrutinib) in combination with obinutuzumab in treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), the most common form of leukemia in adults. This is the first approval for a non-chemotherapy combination regimen for treatment-naïve patients with CLL/SLL, and marks the tenth FDA approval for IMBRUVICA since its U.S. launch in November 2013. The approval expands the label for IMBRUVICA in frontline CLL/SLL beyond its use as a monotherapy to include combination use with obinutuzumab. IMBRUVICA, a Bruton's tyrosine kinase (BTK) inhibitor, is jointly developed and commercialized by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company.

read corporate press release

No Substantial Benefit From Transplantation Reported For A High-Risk Leukemia Subtype

(St. Jude Children’s) Jan 18, 2019 - Checking for minimal residual disease early in treatment can help some young high-risk leukemia patients avoid bone marrow transplantation without compromising their long-term survival reported researchers in a Journal of Clinical Oncology study.

read press release

Adaptive Biotechnologies Announces Medicare Coverage of the clonoSEQ® Assay for MRD Testing in Patients with Multiple Myeloma and Acute Lymphoblastic Leukemia at Multiple Timepoints Throughout Treatment and Remission

(The Business Journals) Jan 17, 2019 - Adaptive Biotechnologies, an immune driven-medicine company, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) and leader in assessing diagnostic technologies through its MolDX program, has established coverage of the clonoSEQ® Assay for Medicare patients with multiple myeloma and B-cell acute lymphoblastic leukemia (ALL).

read article

More Accurate Leukemia Diagnosis Expected As Researchers Refine Leukemia Classification

(St. Jude Children’s) Jan 14, 2019 - New research means more than 90 percent of the most common cases of childhood cancer can now be classified by subtype, an advance likely to fuel precision medicine.

read press release

For Children With Cancer, Hope for New Treatments

(Wall Street Journal) Jan 15, 2019 - The health-care industry is preparing for a new law that researchers say will mean more treatments for pediatric cancers, which are the leading cause of death from disease among children. The legislation, which requires pharmaceuticals companies to test potential cancer drugs on children as well as adults, goes into effect in 2020. Companies already are ramping up and some plan children’s drug trials this year. “It is an incredibly exciting time,” said Crystal Mackall, a pediatric-cancer researcher and professor of pediatrics at Stanford University School of Medicine. “We have lots of drug companies who want to speak with us suddenly. Before, we went hat in hand, cajoling.”

read article (paid subscription required)

New England Journal of Medicine Publishes Positive Results Of The Pivotal Trial Of Cablivi® (Caplacizumab) For Rare Blood Clotting Disorder

(Sanofi) Jan 9, 2019 - HERCULES Phase 3 trial met its primary endpoint, demonstrating that treatment with Cablivi resulted in a significantly faster time to platelet count response in patients with acquired thrombotic thrombocytopenic purpura (aTTP) when administered in conjunction with plasma exchange and immunosuppression. Cablivi was associated with a significant reduction in aTTP-related death, recurrence, or at least one major thromboembolic event while patients were on treatment, the study's first key secondary endpoint. Cablivi was approved by the European Commission in August 2018.

read corporate press release

miRagen Announces New Clinical Data in Patients With Three Different Types of Blood Cancers Treated With Cobomarsen

(NASDAQ) Jan 10, 2019 - miRagen Therapeutics, Inc. today announced data from its Phase 1 clinical trial evaluating the safety, tolerability and efficacy of cobomarsen, an inhibitor of microRNA-155, in cutaneous T-cell lymphoma (CTCL) and in adult T-cell leukemia/lymphoma (ATLL). The Company will also discuss initial clinical experience in treating diffuse large B-cell lymphoma (DLBCL) patients with cobomarsen.

read article

NantKwest Announces Launch of Merkel Cell Carcinoma Phase II Trial Deploying Novel Triple Combination of off-the-Shelf Natural Killer haNKⓇ Cell Therapy with Superagonist IL-15 Cytokine Therapy and PD-L1 Checkpoint Inhibitor Therapy

(BioSpace) Jan 9, 2019 - Study tests elimination of chemotherapy and expands upon previous combination study of NK Cell Therapy With N-803 showing promising clinically meaningful responses in Merkel Cell Carcinoma patients.

read article

Rafael Pharmaceuticals Announces Initiation of Patient Enrollment for Phase II Clinical Trial of CPI-613 for Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia

(P&T Community) Jan 8, 2019 - Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of patient enrollment for a phase II clinical trial of CPI-613 for patients with relapsed or refractory Burkitt Lymphoma/Leukemia.

read article
Next Page